

## Special Issue

# Novel Biomarker and Treatments for Diabetic Neuropathy

### Message from the Guest Editors

We invite researchers to submit original studies for a special edition of *Biomedicines* focused on diabetic neuropathy. This issue will highlight cutting-edge clinical and preclinical research, including molecular science and animal models, that explore novel therapeutic options. We are particularly interested in studies examining the effects of new and potential treatments on disease mechanisms and patient-related outcomes, as well as research on the role of existing pharmaceuticals in managing diabetic neuropathy. Ultimately, this edition aims to advance therapeutic interventions and improve clinical care for individuals affected by diabetes. All submissions will undergo peer review, and accepted articles will be published in a high-visibility edition of *Biomedicines*. We look forward to receiving your contribution to this critical area of medical science.

### Guest Editors

Prof. Dr. Arun V. Krishnan

1. School of Clinical Medicine, University of New South Wales Sydney, Kensington, NSW 2033, Australia
2. Department of Neurology, Prince of Wales Hospital, Sydney, NSW 2031, Australia

Dr. Tushar Issar

School of Clinical Medicine, University of New South Wales Sydney, Kensington, NSW 2033, Australia

### Deadline for manuscript submissions

31 December 2025



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/223262](https://mdpi.com/si/223262)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).